Condition
Unresectable Basal Cell Carcinoma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03816332Phase 1Active Not Recruiting
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
NCT05896839Phase 1Recruiting
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT07576725Phase 2Not Yet Recruiting
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Showing all 3 trials